Literature DB >> 2749185

Subjective experience of schizophrenia.

J Cutting1, F Dunne.   

Abstract

A standardized assessment of the subjective experience of schizophrenia and depression was developed in three stages: (1) An open-ended interview covering changes in nine areas of psychological functioning was given to acute, remitted, and chronic schizophrenic patients, and to depressed patients. (2) On the basis of their replies, a structured interview was given on two separate occasions close in time to 20 remitted schizophrenic patients by two different interviewers to test interrater reliability, and to the same 20 remitted patients 6 months later by one interviewer to test intertemporal reliability. (3) The most reliable items were retained in a final version, from which the replies of a new group of 20 remitted depressed and the 20 remitted schizophrenic patients could be compared. Despite the long interval that usually had elapsed between the first episode of illness and the time of questioning, most patients gave a detailed account of their experiences that did not vary much either 6 months later or in an interview by a different psychiatrist. The most reliable items concerned changes in perception, and these also best distinguished the experiences of schizophrenia from those of depression. Perceptual dysfunction appears to be the most invariant feature of the early stage of schizophrenia, but a qualitative disturbance of thinking also occurs.

Entities:  

Mesh:

Year:  1989        PMID: 2749185     DOI: 10.1093/schbul/15.2.217

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  12 in total

1.  Phenomenological dimensions of sensory gating.

Authors:  William P Hetrick; Molly A Erickson; David A Smith
Journal:  Schizophr Bull       Date:  2010-06-04       Impact factor: 9.306

Review 2.  Review of the operational definition for first-episode psychosis.

Authors:  Nicholas J K Breitborde; Vinod H Srihari; Scott W Woods
Journal:  Early Interv Psychiatry       Date:  2009-11       Impact factor: 2.732

3.  The meaning of community rehabilitation for schizophrenia patients in Israel.

Authors:  Uri Mazor; Israel Doron
Journal:  Community Ment Health J       Date:  2010-09-14

4.  Subcortical visual dysfunction in schizophrenia drives secondary cortical impairments.

Authors:  Pamela D Butler; Antigona Martinez; John J Foxe; Dongsoo Kim; Vance Zemon; Gail Silipo; Jeannette Mahoney; Marina Shpaner; Maria Jalbrzikowski; Daniel C Javitt
Journal:  Brain       Date:  2006-09-19       Impact factor: 13.501

5.  Abnormal subjective experiences in schizophrenia: its relationships with neuropsychological disturbances and frontal signs.

Authors:  M J Cuesta; V Peralta; J A Juan
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1996       Impact factor: 5.270

6.  Why do persons with bipolar disorder stop their medication?

Authors:  Kavi K Devulapalli; Rosalinda V Ignacio; Peter Weiden; Kristin A Cassidy; Tiffany D Williams; Roknedin Safavi; Frederic C Blow; Martha Sajatovic
Journal:  Psychopharmacol Bull       Date:  2010

Review 7.  The default-mode, ego-functions and free-energy: a neurobiological account of Freudian ideas.

Authors:  R L Carhart-Harris; K J Friston
Journal:  Brain       Date:  2010-02-28       Impact factor: 13.501

8.  The self-assessment scale of cognitive complaints in schizophrenia: a validation study in Tunisian population.

Authors:  Ines Johnson; Oussama Kebir; Olfa Ben Azouz; Lamia Dellagi; Yasmine Rabah; Karim Tabbane
Journal:  BMC Psychiatry       Date:  2009-10-08       Impact factor: 3.630

Review 9.  The Phenomenology and Neurobiology of Visual Distortions and Hallucinations in Schizophrenia: An Update.

Authors:  Steven M Silverstein; Adriann Lai
Journal:  Front Psychiatry       Date:  2021-06-11       Impact factor: 4.157

10.  Looking at the schizophrenia spectrum through the prism of self-disorders: an empirical study.

Authors:  Andrea Raballo; Ditte Sæbye; Josef Parnas
Journal:  Schizophr Bull       Date:  2009-06-15       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.